Loading
Biotechnology
9 min read
Areas of Expertise :
Biotechnology, Pharmaceutical, Immunology, Patent, Intellectual Property
Published Date:
Last Modified Date:
Jurisdiction:
Federal. U.S. Supreme Court
Court:
Amgen Inc. v. Sanofi is a U.S. Supreme Court decision involving patent enablement, biologics, antibody-based drug development, and pharmaceutical patent litigation. The dispute centered on whether Amgen’s patents, which claimed a broad class of monoclonal antibodies designed to lower LDL cholesterol by blocking the PCSK9 protein, satisfied the enablement requirement under 35 U.S.C. § 112(a).
The case examined how much technical detail a patent must provide when it claims a wide genus of therapeutic antibodies based mainly on function rather than exact amino acid sequences or other structural features. The Supreme Court reaffirmed that a patent claiming a broad class must teach skilled artisans how to make and use the claimed invention across its full scope without undue experimentation.
The litigation arose from competing PCSK9 inhibitor therapies. Amgen developed and marketed Repatha, while Sanofi and Regeneron developed Praluent, a competing PCSK9 antibody therapy. Sanofi and Regeneron challenged Amgen’s patents, arguing that the claims covered a broad range of antibodies without enough technical instruction to support that breadth.
The dispute later centered on two Amgen patents issued in 2014: U.S. Patent No. 8,829,165, issued on September 9, 2014, and U.S. Patent No. 8,859,741, issued on October 14, 2014. The asserted claims covered monoclonal antibodies defined by their ability to bind to specified regions of the PCSK9 protein and block PCSK9 from interacting with LDL receptors. Rather than claiming only specific amino acid sequences, the patents sought protection for a broad antibody genus tied to those binding and blocking functions.
On October 17, 2014, Amgen filed a patent infringement action in the U.S. District Court for the District of Delaware against Sanofi-related entities and Regeneron. The original complaint asserted U.S. Patent Nos. 8,563,698, 8,829,165, and 8,859,741, although the later Supreme Court dispute focused on claims from the ’165 and ’741 patents. Sanofi and Regeneron denied liability and challenged the validity of the asserted claims, including under the enablement and written description requirements.
The case proceeded to a jury trial in March 2016 after the parties stipulated to infringement of selected claims. That stipulation narrowed much of the trial to patent validity issues, with enablement and written description becoming major points of dispute under 35 U.S.C. § 112. Obviousness also remained part of the broader validity litigation, although the later appeals centered mainly on written description and enablement.
Sanofi and Regeneron argued that Amgen’s patent specifications did not teach skilled artisans how to make and use the claimed antibody genus without undue experimentation. The jury found that Sanofi and Regeneron had not proven the asserted claims invalid. After the verdict, the case moved to appellate review of the district court’s evidentiary rulings, jury instructions, and injunction order.
On October 5, 2017, the U.S. Court of Appeals for the Federal Circuit reversed in part, affirmed in part, vacated in part, and remanded the case for further proceedings. The appellate court found errors involving the exclusion of certain post-priority-date evidence related to written description and enablement. It also found problems with the jury instruction on written description.
The Federal Circuit vacated the permanent injunction that had been entered against sales of Praluent. The remand returned the dispute to the district court for another trial on patent validity, including whether Amgen’s disclosure was sufficient for the scope of the antibody claims.
After remand, the case returned to the district court for another jury trial on written description and enablement. The remand jury again found that Sanofi and Regeneron had not proven invalidity for the claims that later became central to the enablement appeal. At the same time, the jury found other asserted claims of the ’165 patent invalid for lack of written description.
The district court then granted judgment as a matter of law in favor of Sanofi and Regeneron on lack of enablement for claims 19 and 29 of the ’165 patent and claim 7 of the ’741 patent. The court concluded that Amgen’s specifications disclosed a limited set of antibodies and relied too heavily on screening, substitution, and additional experimentation to reach the full claimed genus. As a result, those asserted claims were held invalid despite Amgen’s jury verdict on them.
On February 11, 2021, the Federal Circuit affirmed the district court’s judgment that the asserted claims were invalid for lack of enablement. The court agreed that Amgen’s disclosure was not commensurate with the breadth of claims that covered antibodies defined by multiple functional requirements.
The decision addressed the work required to make and screen candidate antibodies to determine whether they satisfied the claimed binding and blocking limitations. The Federal Circuit held that the claims were not enabled across their full scope because skilled artisans would need to engage in substantial trial-and-error work to identify antibodies falling within the claims.
On May 18, 2023, the U.S. Supreme Court issued a unanimous decision affirming the Federal Circuit’s judgment. The Court held that when a patent claims an entire class of compositions, the specification must enable skilled artisans to make and use that class without undue experimentation.
The Court rejected Amgen’s argument that its disclosed antibody examples, research roadmap, and conservative substitution method were enough to support broad functional genus claims. The problem was not that Amgen claimed antibodies by function alone. The problem was that the patents gave skilled artisans examples and research methods for finding more antibodies, but did not provide enough instruction to make and use the full range of antibodies covered by the claims. The ruling did not eliminate genus claims, but it made clear that broad patent claims require disclosure that matches the scope of what is claimed.
Supreme Court of the United States
Case Name:
Amgen Inc. v. Sanofi
Patent Dispute
Patent Infringement
Patent Infringement and Validity Expertise
Patent Prosecution
Biopharmaceutical
Drug Development
Molecular Biology
Protein
Amgen Inc. v. Sanofi is a U.S. Supreme Court decision involving patent enablement, biologics, antibody-based drug development, and pharmaceutical patent litigation. The dispute centered on whether Amgen’s patents, which claimed a broad class of monoclonal antibodies designed to lower LDL cholesterol by blocking the PCSK9 protein, satisfied the enablement requirement under 35 U.S.C. § 112(a).
The case examined how much technical detail a patent must provide when it claims a wide genus of therapeutic antibodies based mainly on function rather than exact amino acid sequences or other structural features. The Supreme Court reaffirmed that a patent claiming a broad class must teach skilled artisans how to make and use the claimed invention across its full scope without undue experimentation.
The litigation arose from competing PCSK9 inhibitor therapies. Amgen developed and marketed Repatha, while Sanofi and Regeneron developed Praluent, a competing PCSK9 antibody therapy. Sanofi and Regeneron challenged Amgen’s patents, arguing that the claims covered a broad range of antibodies without enough technical instruction to support that breadth.
The dispute later centered on two Amgen patents issued in 2014: U.S. Patent No. 8,829,165, issued on September 9, 2014, and U.S. Patent No. 8,859,741, issued on October 14, 2014. The asserted claims covered monoclonal antibodies defined by their ability to bind to specified regions of the PCSK9 protein and block PCSK9 from interacting with LDL receptors. Rather than claiming only specific amino acid sequences, the patents sought protection for a broad antibody genus tied to those binding and blocking functions.
On October 17, 2014, Amgen filed a patent infringement action in the U.S. District Court for the District of Delaware against Sanofi-related entities and Regeneron. The original complaint asserted U.S. Patent Nos. 8,563,698, 8,829,165, and 8,859,741, although the later Supreme Court dispute focused on claims from the ’165 and ’741 patents. Sanofi and Regeneron denied liability and challenged the validity of the asserted claims, including under the enablement and written description requirements.
The case proceeded to a jury trial in March 2016 after the parties stipulated to infringement of selected claims. That stipulation narrowed much of the trial to patent validity issues, with enablement and written description becoming major points of dispute under 35 U.S.C. § 112. Obviousness also remained part of the broader validity litigation, although the later appeals centered mainly on written description and enablement.
Sanofi and Regeneron argued that Amgen’s patent specifications did not teach skilled artisans how to make and use the claimed antibody genus without undue experimentation. The jury found that Sanofi and Regeneron had not proven the asserted claims invalid. After the verdict, the case moved to appellate review of the district court’s evidentiary rulings, jury instructions, and injunction order.
On October 5, 2017, the U.S. Court of Appeals for the Federal Circuit reversed in part, affirmed in part, vacated in part, and remanded the case for further proceedings. The appellate court found errors involving the exclusion of certain post-priority-date evidence related to written description and enablement. It also found problems with the jury instruction on written description.
The Federal Circuit vacated the permanent injunction that had been entered against sales of Praluent. The remand returned the dispute to the district court for another trial on patent validity, including whether Amgen’s disclosure was sufficient for the scope of the antibody claims.
After remand, the case returned to the district court for another jury trial on written description and enablement. The remand jury again found that Sanofi and Regeneron had not proven invalidity for the claims that later became central to the enablement appeal. At the same time, the jury found other asserted claims of the ’165 patent invalid for lack of written description.
The district court then granted judgment as a matter of law in favor of Sanofi and Regeneron on lack of enablement for claims 19 and 29 of the ’165 patent and claim 7 of the ’741 patent. The court concluded that Amgen’s specifications disclosed a limited set of antibodies and relied too heavily on screening, substitution, and additional experimentation to reach the full claimed genus. As a result, those asserted claims were held invalid despite Amgen’s jury verdict on them.
On February 11, 2021, the Federal Circuit affirmed the district court’s judgment that the asserted claims were invalid for lack of enablement. The court agreed that Amgen’s disclosure was not commensurate with the breadth of claims that covered antibodies defined by multiple functional requirements.
The decision addressed the work required to make and screen candidate antibodies to determine whether they satisfied the claimed binding and blocking limitations. The Federal Circuit held that the claims were not enabled across their full scope because skilled artisans would need to engage in substantial trial-and-error work to identify antibodies falling within the claims.
On May 18, 2023, the U.S. Supreme Court issued a unanimous decision affirming the Federal Circuit’s judgment. The Court held that when a patent claims an entire class of compositions, the specification must enable skilled artisans to make and use that class without undue experimentation.
The Court rejected Amgen’s argument that its disclosed antibody examples, research roadmap, and conservative substitution method were enough to support broad functional genus claims. The problem was not that Amgen claimed antibodies by function alone. The problem was that the patents gave skilled artisans examples and research methods for finding more antibodies, but did not provide enough instruction to make and use the full range of antibodies covered by the claims. The ruling did not eliminate genus claims, but it made clear that broad patent claims require disclosure that matches the scope of what is claimed.
Biotechnology Expert Witness
A biotechnology expert witness may explain antibody structure, antigen binding, protein interactions, and biological variability. In a dispute involving PCSK9 antibodies, this type of expert may address how antibodies bind to particular regions of PCSK9, how blocking PCSK9 affects LDL receptor activity, and how predictable antibody behavior is when claims are based on function rather than sequence.
Antibody Drug Development Expert Witness
An antibody drug development expert witness may explain drug discovery workflows, antibody generation, screening assays, laboratory testing, and therapeutic candidate selection. In litigation involving functional antibody genus claims, this type of expert may address the amount of experimentation needed to move from disclosed examples to additional antibodies that satisfy the claimed binding and blocking requirements.
Patent Prosecution Expert Witness
A patent prosecution expert witness may explain patent drafting practice, prosecution history, claim scope, and how technical disclosures are presented during examination. In pharmaceutical patent disputes, this type of expert may provide context on the relationship between the specification, claim language, and the inventor’s disclosed work, while the legal standards remain for the court.
Functional Genus Claims and Full-Scope Enablement
Amgen Inc. v. Sanofi addressed broad functional genus claims that were not supported by detailed technical disclosure across the claimed antibody class. A broad patent claim must teach skilled artisans how to make and use the invention across its claimed scope. In antibody patent litigation, that inquiry may focus on whether the patent provides enough working examples, structural information, sequence data, common features, or other technical guidance to support the range of antibodies covered by the claims.
Technical Evidence in Patent Enablement Challenges
Enablement disputes often involve scientific evidence about predictability, experimental burden, and whether the claimed invention reflects a completed technical contribution. In biologics litigation, courts may examine how much trial-and-error work remains after reading the patent. The analysis may also consider whether skilled artisans can practice the claimed invention based on the patent disclosure or must conduct additional research to identify antibodies that fall within the claim language.
Patent Drafting and Prosecution for Biologics Claims
Following Amgen Inc. v. Sanofi, patent applicants seeking genus claims in biotechnology and pharmaceutical portfolios rely on representative examples, structural information, sequence data, and concrete technical guidance. Functional claim language must be supported by a specification that teaches more than a research pathway. For biologics claims, the patent disclosure may need to connect the claimed function to enough technical detail for skilled artisans to make and use the claimed antibody class without excessive screening or follow-on experimentation.
Pharmaceutical Patent Portfolio Strategy for Biologics
The ruling affects how pharmaceutical companies assess exclusivity, claim breadth, disclosure obligations, and competitive risk in biologics and platform-technology patents. Companies pursuing antibody-based therapies must balance broad patent protection with the technical disclosure required to withstand enablement challenges. Patent portfolio decisions may involve narrower claims, additional working examples, structural disclosures, continuation strategies, and claim sets tied more closely to the inventor’s demonstrated work.
Amgen Inc. v. Sanofi moved from competing PCSK9 antibody products to two jury trials, Federal Circuit review, and final Supreme Court resolution. Amgen prevailed before juries on the claims that later reached the enablement appeal, although the remand jury invalidated other asserted claims. The district court later entered judgment for Sanofi and Regeneron on lack of enablement, the Federal Circuit affirmed that ruling, and the Supreme Court unanimously agreed that Amgen’s broad antibody claims were not enabled across their full scope.
The final result left Sanofi and Regeneron with a successful enablement challenge to the asserted Amgen claims. The Court’s ruling stated that a patent claiming a large class of possible therapies must teach skilled artisans how to make and use that class, rather than leaving them to identify much of it through further research.
What did Amgen Inc. v. Sanofi involve?
The case involved Amgen patents claiming a broad class of PCSK9-blocking monoclonal antibodies. Sanofi and Regeneron challenged the asserted claims on enablement and written description grounds.
Which Amgen patent claims reached the Supreme Court enablement dispute?
The Supreme Court dispute focused on claims 19 and 29 of U.S. Patent No. 8,829,165 and claim 7 of U.S. Patent No. 8,859,741. Those claims covered antibodies defined by binding and blocking functions related to PCSK9.
Did the Supreme Court eliminate genus claims in biotechnology?
No. The Supreme Court did not eliminate genus claims. It held that genus claims must be supported by enough technical disclosure to enable the claimed class without undue experimentation.
Why were Amgen’s antibody claims held invalid?
The courts found that Amgen’s patents claimed a broad class of PCSK9-blocking antibodies but did not teach skilled artisans how to make and use the full range of antibodies covered by the claims. The disclosures provided examples and research methods, but not enough guidance for the claimed genus.
What did the Supreme Court decide in 2023?
The Supreme Court unanimously affirmed the Federal Circuit’s judgment. It held that Amgen’s asserted antibody claims were invalid for lack of enablement because the patents did not enable the full scope of the claimed genus.
Biotechnology Expert Witness
A biotechnology expert witness may explain antibody structure, antigen binding, protein interactions, and biological variability. In a dispute involving PCSK9 antibodies, this type of expert may address how antibodies bind to particular regions of PCSK9, how blocking PCSK9 affects LDL receptor activity, and how predictable antibody behavior is when claims are based on function rather than sequence.
Antibody Drug Development Expert Witness
An antibody drug development expert witness may explain drug discovery workflows, antibody generation, screening assays, laboratory testing, and therapeutic candidate selection. In litigation involving functional antibody genus claims, this type of expert may address the amount of experimentation needed to move from disclosed examples to additional antibodies that satisfy the claimed binding and blocking requirements.
Patent Prosecution Expert Witness
A patent prosecution expert witness may explain patent drafting practice, prosecution history, claim scope, and how technical disclosures are presented during examination. In pharmaceutical patent disputes, this type of expert may provide context on the relationship between the specification, claim language, and the inventor’s disclosed work, while the legal standards remain for the court.
Functional Genus Claims and Full-Scope Enablement
Amgen Inc. v. Sanofi addressed broad functional genus claims that were not supported by detailed technical disclosure across the claimed antibody class. A broad patent claim must teach skilled artisans how to make and use the invention across its claimed scope. In antibody patent litigation, that inquiry may focus on whether the patent provides enough working examples, structural information, sequence data, common features, or other technical guidance to support the range of antibodies covered by the claims.
Technical Evidence in Patent Enablement Challenges
Enablement disputes often involve scientific evidence about predictability, experimental burden, and whether the claimed invention reflects a completed technical contribution. In biologics litigation, courts may examine how much trial-and-error work remains after reading the patent. The analysis may also consider whether skilled artisans can practice the claimed invention based on the patent disclosure or must conduct additional research to identify antibodies that fall within the claim language.
Patent Drafting and Prosecution for Biologics Claims
Following Amgen Inc. v. Sanofi, patent applicants seeking genus claims in biotechnology and pharmaceutical portfolios rely on representative examples, structural information, sequence data, and concrete technical guidance. Functional claim language must be supported by a specification that teaches more than a research pathway. For biologics claims, the patent disclosure may need to connect the claimed function to enough technical detail for skilled artisans to make and use the claimed antibody class without excessive screening or follow-on experimentation.
Pharmaceutical Patent Portfolio Strategy for Biologics
The ruling affects how pharmaceutical companies assess exclusivity, claim breadth, disclosure obligations, and competitive risk in biologics and platform-technology patents. Companies pursuing antibody-based therapies must balance broad patent protection with the technical disclosure required to withstand enablement challenges. Patent portfolio decisions may involve narrower claims, additional working examples, structural disclosures, continuation strategies, and claim sets tied more closely to the inventor’s demonstrated work.
Amgen Inc. v. Sanofi moved from competing PCSK9 antibody products to two jury trials, Federal Circuit review, and final Supreme Court resolution. Amgen prevailed before juries on the claims that later reached the enablement appeal, although the remand jury invalidated other asserted claims. The district court later entered judgment for Sanofi and Regeneron on lack of enablement, the Federal Circuit affirmed that ruling, and the Supreme Court unanimously agreed that Amgen’s broad antibody claims were not enabled across their full scope.
The final result left Sanofi and Regeneron with a successful enablement challenge to the asserted Amgen claims. The Court’s ruling stated that a patent claiming a large class of possible therapies must teach skilled artisans how to make and use that class, rather than leaving them to identify much of it through further research.
What did Amgen Inc. v. Sanofi involve?
The case involved Amgen patents claiming a broad class of PCSK9-blocking monoclonal antibodies. Sanofi and Regeneron challenged the asserted claims on enablement and written description grounds.
Which Amgen patent claims reached the Supreme Court enablement dispute?
The Supreme Court dispute focused on claims 19 and 29 of U.S. Patent No. 8,829,165 and claim 7 of U.S. Patent No. 8,859,741. Those claims covered antibodies defined by binding and blocking functions related to PCSK9.
Did the Supreme Court eliminate genus claims in biotechnology?
No. The Supreme Court did not eliminate genus claims. It held that genus claims must be supported by enough technical disclosure to enable the claimed class without undue experimentation.
Why were Amgen’s antibody claims held invalid?
The courts found that Amgen’s patents claimed a broad class of PCSK9-blocking antibodies but did not teach skilled artisans how to make and use the full range of antibodies covered by the claims. The disclosures provided examples and research methods, but not enough guidance for the claimed genus.
What did the Supreme Court decide in 2023?
The Supreme Court unanimously affirmed the Federal Circuit’s judgment. It held that Amgen’s asserted antibody claims were invalid for lack of enablement because the patents did not enable the full scope of the claimed genus.
Patent Dispute
Patent Infringement
Patent Infringement and Validity Expertise
Patent Prosecution
Biopharmaceutical
Drug Development
Molecular Biology
Protein
Biotechnology, +4
Biotechnology